Dear Colleagues, Presenting OncoAlert Horizons | Focus: Breast Cancer Educational Series 🚨In this session, we explore: Adjuvant Treatment Challenges in Early HR /HER2− #BreastCancer Emerging Role of Next-Gen Oral SERDs 🧑‍⚕️Faculty: Dr. Sibylle Loibl🇩🇪and Dr. Rupert Bartsch🇩🇪 HORIZONS 🌅Faculty @LoiSher 🇦🇺 @JavierCortesMD 🇪🇸 @BarbaraPistill2 🇫🇷 @BianchiniGP 🇮🇹 @ElisaAgostinett 🇧🇪 Sybille Loibl 🇩🇪 Rupert Barsch 🇩🇪 Francois Clement Bidard 🇫🇷 Cristina Saura 🇪🇸 Pinging our #BreastCancer Faculty @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @double_whammied @maryam_lustberg @raalbany @hoperugo @stolaney1 @LoiSher @SirohiBhawna @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @weoncologists @OncoAlert @nataliagandur @FernandoOnco @ElisaAgostinett @to_be_elizabeth @realbowtiedoc @Lucarecco @GaiaGriguolo @MarioBalsaMD This OncoAlert Horizons educational series was supported by an unrestricted educational grant from Roche. All content was independently d

Join the 27th Annual International Lung Cancer Congress® for a high-impact update on lung cancer care, featuring the latest in immunotherapy, targeted therapy, ADCs, and multidisciplinary management. 👉 Don’t miss it—REGISTER FREE with code OncoAlert. buff.ly/YnjTuRM LIVE EVENT :Huntington Beach, California Includes expert case discussions, keynote lecture, and a forward-looking panel on where the field is heading. Brought to you by our collaborators at PER #LungCancer @DDoroshow @peters_solange @riess_md @HendriksLizza @MNagasaka @ReckampK @drgandara @christine_lovly @PatelOncology @TonyMok9 @CoreyLangerMD @HwakeleeMD @marinagarassino. @HosseinBorghaei @DrRoyHerbstYale @PatelOncology

💡 Insights from #ESTRO26 show how national audit programmes use benchmarking, peer review, and independent dosimetric verification to reduce practice variation (like contouring) and catch potential errors before they reach the patient. 👉 bit.ly/4ooin1s #RadOnc

Kudos to the phenomenal team on these impactful publications in @CircAHA & @JCO_ASCO, two of the premier journals in #cardiology & #oncology, respectively! I had the pleasure of meeting with @avirupguha through his collaboration with @neerajaiims - impressive to see these joint efforts maturing over the years & getting synthesized into useful, practical guidance for trial design. Particularly like the figure below, which distills in the lower panel how to integrate various CV endpoints.

🔥 Trop 2 pan-cancer, normal tissue and single cell expression analysis just out in NPJ precision oncology Tissue distribution explain on-target off-tumor side effects such as mucositis Methylation is key regulatory mechanism More 👇👇👇 @OncoAlert @Larvol @NaturePortfolio

4/12 — Figure 1 simplified Figure 1, simplified: Start with mechanism of action or early signal. Identify the likely CV toxicity pathway. Then choose the endpoint and tool that match the biology. Right question → right tool. @peters_solange @GlopesMd @herbloong @BalazsHalmosMD @christine_lovly @BenjaminBesseMD @DrSanjayPopat @OncoAlert #Phase1 #ClinicalTrials #CardioOncology

Monday Morning Mention! 🩺 Study Protocol of OLIGOPELVIS 2–GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate Cancer by Quentin Josset...Stéphane Supiot et al buff.ly/59gPQOj 💡 Patient summary The OLIGOPELVIS 2–GETUG P12 clinical trial assesses short-term (6 mo) androgen-deprivation therapy in association with external beam radiation therapy in men with prostate cancer relapsing to pelvic and para-aortic lymph nodes of prostate cancer. The trial investigates whether radiotherapy targeting pelvic and para-aortic lymph nodes can improve the biological response while maintaining a favorable tolerability profile. ✨ We thank the authors for trusting EUO to publish your work. @uroweb @mroupret @GPloussard @jteoh_hk @Ric_Campi @CaPsurvivorship @LauraMarandino @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect

A new option for PTEN deficient metastatic #prostatecancer! Capivasertib with abiraterone added to ADT backbone, now FDA approved. @OncoAlert @utswcancer

🔥Fascinating - explaining cisplatin-induced neurotoxicity!🔥 DNA repair drives cisplatin-induced neuronal death in @CellPressNews cell.com/cell/fulltext/S0092…

ER /HER2- metastatic breast cancer: ESMO Breast Cancer 2026 Satellite Symposium highlights Experts discuss 2nd line treatment strategies and sequencing following ET CDK4/6i in endocrine therapy–eligible patients with ER /HER2− mBC Topics include: >> Overview of current ESMO guidelines >> Intrinsic and acquired endocrine resistance after 1L ET CDK4/6i >> Role of biomarker-selected endocrine-based therapies and key clinical trial data >> Clinical relevance of 𝐸𝑆𝑅1 mutations and testing strategies Watch the video in this post 📺 This programme has been sponsored by Menarini Stemline and is intended for HCPs only. Brought to you by COR2ED Medical Affairs.

10/12 — Statistics Statisticians need to be in the room early. Key choices: ITT vs as-treated on-treatment vs long-term window rare-event sensitivity multiplicity competing risks pooling across trials signal detection vs labeling-grade evidence Absence of signal ≠ absence of risk. @ConquerCancerFd @ASCOPres @CD_AACR @HeartNews @ASH_hematology @ASTRO_org @SITCancer @OncoAlert #StatsTwitter #ClinicalTrials

Very important and relevant work bridging cardiology and oncology in @CircAHA ! Bravo @neerajaiims and team ! @ASCO @JCO_ASCO @American_Heart @OncoAlert

Out now in @JCO_ASCO and @CircAHA: Our @American_Heart & @ASCO joint scientific statement on defining cardiovascular (CV) endpoints in oncology trials👉a framework for asking CV safety questions before trials begin👉Article link in the last post 👇#CardioOncology #CardioTwitter. @OncoAlert @US_FDA

11/12 — Figure 2 / operations Figure 2 is the implementation map. Trial phase → CRFs → CEC → DMC → decentralized tools → PROs → statistical/regulatory alignment. Goal: make CV safety signals interpretable without making oncology trials unnecessarily burdensome. @ASH_hematology @ASTRO_org @SITCancer @OncoAlert @CancerNetwork @OncLive #DrugDevelopment #ClinicalResearch

📊 Cancer incidence in young adults (20–49 y) in Spain 📈 Increasing: 🔹 CRC, GC, breast & cervical (<40 y) 🔹 PDAC (women) 🔹 Kidney & thyroid (men) 📉 Decreasing: 🔹 Lung, laryngeal, bladder & liver 🎯 Opposing trends: ↓ smoking-related, ↑ obesity-associated. 🔗 doi.org/10.1016/j.ejca.2026.… @OncoAlert

🏥 When health care costs rise, some patients may forgo needed care. New research found higher out-of-pocket costs were associated with cost-related care avoidance among adults with and without a history of cancer. Read the full study: acsjournals.onlinelibrary.wi… @OncoAlert

Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial buff.ly/b0oOt8I In this phase III randomized trial of 660 biopsy-naïve men with high clinical suspicion of prostate cancer but non-suspicious or equivocal MRI findings, ^68Ga-PSMA-11 PET/CT-guided evaluation was non-inferior to standard systematic biopsy for detecting clinically significant #ProstateCancer (12% vs 16%). Importantly, PSMA PET/CT enabled nearly half of participants (49%) to safely avoid biopsy while maintaining diagnostic accuracy. These findings suggest PSMA PET/CT may refine prostate cancer diagnosis, reducing unnecessary biopsies and associated overdiagnosis. @ButeauJames @DrMHofman @drlouiseemmett @declangmurphy @veerukasi @DrDanielMoon @DrScottLeslie @szetinglee1 @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin #OncoAlertAF @nataliagandur @realbowtiedoc @Onco_Cifu88 @scocmem

Lung cancer 🫁 update from #ASCO26 👉 buff.ly/9P3rYdv Renowned lung cancer experts join our collaborators at @COR2EDMedEd at ASCO 2026 to discuss breaking data emerging from the meeting. Watch the video updates for insights on HER2-mutant non-small cell lung cancer (NSCLC) from Drs Herbert Loong and Isabel Preeshagul, and analysis of other key lung cancer trial data from Prof. Mark Socinski. #LungCancer #NSCLC #SCLC @herbloong @ipreeshagul

Reimagining HER2 therapy: Bridging oncogene addiction and immune modulation dlvr.it/TT36sM

🇪🇸 ES 🔬 GUARD Consortium impulsa #REINFORCE, un ensayo clínico internacional de Fase III en cáncer de próstata metastásico hormonosensible. Intensificación de tratamiento con Docetaxel Apalutamida en pacientes sin respuesta profunda de PSA. 📅 FSA: Junio 2026 | FPI: Julio 2026 #OncologíaUrinaria #CáncerDePróstata #EnsayoClínico 🇬🇧 EN 🔬 GUARD Consortium launches #REINFORCE, a Phase III randomized international clinical trial in metastatic hormone-sensitive prostate cancer. Treatment intensification with Docetaxel Apalutamide for patients without deep PSA response. 📅 FSA: June 2026 | FPI: July 2026 #ProstateCancer #ClinicalTrial #Oncology @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1